INTRODUCTION
Over the last decade, significant technological advances have allowed the scientific community to measure over one million single-nucleotide polymorphisms (SNPs) in a single assay. These technologies are the fundamental keystones of the phenotype-togenotype strategy of studying human genetics commonly identified as a 'genome-wide association study' (GWAS). Many of these GWAS results have been curated by the National Human Genome Research Institute 'Catalog of Published GWASs.' This repository contains over 1600 genome-wide significant genomic markers (Po5.0E-8) for over 250 traits (https://www.genome.gov/ 26525384). 1 One of the challenges in conducting GWASs is identifying specific clinically defined traits with clear correspondence to an underlying genetic component. Even when such traits are observed, GWASs often fail to explain much of the variability exhibited by subjects under study. 2 This is exemplified in one of the largest GWASs conducted to date, which focused on human height in 183 727 participants. Although human height is believed to be 480% heritable, 10.5% of the phenotypic variance can be explained by 180 genome-wide statistically significant SNPs. 3 The challenge of identifying markers associated with any phenotype during a GWAS is compounded further by most statistically significant markers having marginal effect sizes. The few exceptions to this include variants describing many common HLA haplotypes including HLA-DRB1*1501.
HLA-DRB1 encodes an important component of the human leukocyte antigen (HLA) class II histocompatibility complex necessary for antigen presentation. Not surprisingly, variants in and around this gene have been associated with numerous autoimmune diseases by GWAS analysis including: rheumatoid arthritis, [4] [5] [6] [7] [8] [9] juvenile arthritis, 10 Graves disease, 11 type 1 diabetes, 12 systemic lupus erythematous, 13 ulcerative colitis 14 and multiple sclerosis (MS). [15] [16] [17] [18] In addition, variants in and around HLA-DRB1 have been associated with drug-induced liver injury. 19, 20 The association of common genetic variants in HLA-DRB1 with numerous disease phenotypes suggests that HLA-DRB1 may be a pivotal gene involved in overall human health.
In addition to enormous amounts of genomic data being generated and stored for scientific study as the result of GWASs, substantial amounts of phenotypic data are also being stored in the form of electronic medical records (EMRs). EMR data can contain intimate long-term medical histories including physician notes, imaging results, laboratory results, medication records, family histories and billing information-most notably tracked by the International Classification of Disease version 9-CM (ICD9) and 'V' codes, a standardized hierarchical coding system to define patient care. These multi-level ICD9/V codes not only support a standardized mechanism for billing purposes, but provide insight into thousands of disease phenotypes. Not surprisingly, ICD9 codes are commonly used to define disease status for genetic studies, but these studies typically focus on one specific disease. 21 Where GWASs start with a phenotype and attempt to define a predictive genotype, it is now possible to go in the reverse direction, where the genetic variant is associated with the entire content of the EMR to define many phenotypes. This approach has been termed phenome-wide association study (PheWAS). The PheWAS strategy may help address some of the limitations of the GWAS approach, specifically as it relates to phenotypic constraints.
Only a handful of PheWASs have been conducted to date, [22] [23] [24] including a proof of principle for the technique using Vanderbilt's DNA biobank (BioVU). 25 SNPs selected for analysis in the BioVU study were chosen based on statistically significant GWAS results published previously. Most notably, one of the SNPs selected included rs3135388, a marker that tags for HLA-DRB1*1501 (r 2 ¼ 0.97). Located about 130 kb from HLA-DRB1, rs3135388 is strongly associated with MS. 26 Of the five SNPs genotyped in 6005 European-Americans in BioVU, four of the five SNPs were validated for association with the ICD9 codes that defined the predicted phenotypes, including the expected association of rs3135388 with MS. In addition to the expected phenotypes, rs3135388 genotype demonstrated novel associations with additional phenotypes including erythematous conditions and benign neoplasm of respiratory and intrathoracic organs. 25 As a result of the pleiotropic nature of HLA-DRB1 and the potential utility of a PheWAS strategy in identifying novel phenotypes associated with HLA-DRB1, we genotyped rs3135388 in 4235 DNA samples from subjects enrolled in Marshfield Clinic's Personalized Medicine Research Project (PMRP) 27 and associated those genotypes with 4841 phenotypes defined by standardized ICD9 and V codes along with site-specific ICD9 codes (Figure 1 ).
RESULTS AND DISCUSSION
Although none of the PheWAS associations met a conservative Bonferroni corrected P-value (Po1.0E-5), interesting associations were observed. Despite a small sample size (n ¼ 20 cases), rs3135388 showed association with the ICD9 code for MS (ICD9 340, P ¼ 0.023) in our cohort, as expected ( Figure 1 , Table 1 ). Interestingly, the ICD9 code for 'benign neoplasm of the respiratory and intrathoracic organs' (ICD9 212) was also associated with rs3135388 genotype (P ¼ 0.042), potentially validating novel results from the BioVU data set. 25 'Benign neoplasm of other parts of the digestive system' was also associated with rs3135388 in our cohort (ICD9 211, P ¼ 0.0023), but in the opposite direction observed in the BioVU data set, suggesting caution should be considered when interpreting these phenotypes (Table 1) . Conversely, if the genetic associations with one or more of these two phenotypes are accurate, chronic inflammation and/or disruption of immune-mediated tumor surveillance may underlie the pathophysiology of these conditions.
The rs3135388 genotype was also associated with erythematous conditions (ICD9 695, P ¼ 0.0054), further confirming the association reported in the BioVU cohort 25 (Tables 1 and 2 ). Although this association does not reach PheWAS significance, restricting the number of independent tests to those reported for rs3135388 in the BioVU cohort (eight), allows for a more disease focused interpretation of the P-value. Under this scenario, ICD9 695 remains significant after a Bonferroni adjustment (Po0.05). Unlike the BioVU cohort, sub-phenotypes of ICD9 695 were analyzed within this cohort including toxic erythema (ICD9 695.0, P ¼ 0.096), erythema multiform (ICD9 695.1, P ¼ 0.45), erythema nodosum (ICD9 695.2, P ¼ 0.48), rosacea (ICD9 695.3, P ¼ 0.028), lupus erythematous (ICD9 695.4, P ¼ 0.28), intertrigo (ICD9 695.89, P ¼ 0.067) and unspecified erythematous conditions (ICD9 695.9, P ¼ 0.84) including the site-specific phenotype chronic erythematous caused by a tick bite (ICD9 695.900, P ¼ 1.0; Table 2 ). These results suggest that rosacea, along with intertrigo, may be contributing to the association observed with erythematous conditions. Interestingly, rosacea and intertrigo are relatively independent of each other based on the lack of overlap (40 patients) observed within the ICD9 695 phenotype (Supplementary Figure 1) .
Within the subset of the PMRP cohort, the strongest rs3135388 PheWAS association observed was with alcohol-induced cirrhosis of the liver (ICD9 571.2, P ¼ 0.00011), with the related phenotype 'unspecified alcohol liver damage' also demonstrating suggestive results (ICD9 571.3, P ¼ 0.018) ( Figure 1 , Table 1 ). As a result of the small number of cases and level of significance, all cases coded for ICD9 571.2 were manually inspected. Of the 11 cases, 7 were confirmed. Of the four that were not confirmed, all had elevated liver enzymes suggesting liver damage, one had a record of 'cirrhosis' without mention of alcohol abuse, whereas the other three had extensive records of alcohol abuse but no evidence of 'cirrhosis' in their EMR. When these four cases were removed from the ICD9 571.2 case group, rs3135388's association with ICD9 571.2 became less significant (P ¼ 0.012). Within the BioVU cohort, these sub-phenotypes were not specifically reported. 25 Although we are not aware of any published relationship between MS and alcohol-induced cirrhosis, Singer et al. 19 demonstrated that the HLA-DRB1*1501 haplotype is associated with lumiracoxib-related liver injury (P ¼ 6.8E-25, odds ratio 5, confidence interval 3.6-7.0). Further, Lucena et al.
14 demonstrated a similar association with amoxicillinclavulanate-induced liver injury (P ¼ 4.8E-14, odds ratio 3.1, confidence interval 2.3-4.2). Although the potential relationship between drug-induced liver damage and alcohol-induced liver damage is enticing, replication studies will be necessary to confirm the potential role of rs3135388 genotype with alcoholinduced liver damage.
The ability to identify statistical significance with any phenotype is limited by the inherent nature of the phenotype(s) being studied (for example, heritability, polygenicity, casecontrol specificity and sample size) in either the GWAS or PheWAS strategy. Conversely, when logical genetic targets are identified, either by their known disease association or potential function, the PheWAS strategy may provide broad insight into the pathophysiology of multiple disease processes. One challenge in conducting a PheWAS is determining how to replicate the findings. Is a case-control study or an independent PheWAS necessary for replication? To determine how many cases and controls are necessary for a disease-specific replication, assumptions on prevalence, allele frequency and effect size must be made but are often best-guest estimates. In a PheWAS, many of the case sizes are small, and accurately estimating these parameters may be difficult. In Supplementary Table 1 , we report the number of cases and controls needed to replicate the top findings (Po0.01) with 80% power. Conversely, when the exact disease of interest to replicate is not known, an independent PheWAS replication may be an alternative approach.
In this study, we demonstrate the first external validation of an EMR-based PheWAS. In addition, we expanded the use of the PheWAS approach by including the majority of rare and common phenotypes within the EMR by using multiple levels of ICD9 and V codes when studying HLA-DRB1*1501. These results may further emphasize the pleiotropic nature of the HLA region, provide further insight into the role of antigen presentation in disease pathogenesis, and may inform new treatment options appropriate for multiple conditions. Importantly, as EMRs are more frequently applied and better tools are developed to define accurate clinical phenotypes within EMRs, the PheWAS strategy may become a powerful complementary/alternative strategy to the GWAS.
MATERIALS AND METHODS
Sample collection and processing of DNA used in this study has been previously described. 21, 27 Briefly, all individuals analyzed were 450 years of age, had over 30 years of EMR data on average, were self-identified as being white/non-Hispanic and were originally selected as subpopulations who met eligibility criteria for inclusion in cohort-based studies examining genetic associations with high-density lipoprotein levels or cataract disease. 28 Written informed consent was acquired for all participants and reviewed by Marshfield Clinic's Institutional Review Board.
In this study, ICD9 and V codes, including a few site-specific codes, formed the basis for defining cases and controls. Individuals whose medical record contained ICD9 codes inclusive of three levels of resolution defined by ICD9 code suffix (for example, ICD9 695, 695.1, 695.11) were designated as a case for that condition at each level, whereas those with no record of these codes in their EMR were classified as controls. Under this scenario, cases for one ICD9 code may be coded as controls for a related ICD9 code (for example, ICD9 695.3 and 695.4) potentially diluting the significance of either if both share a common genetic etiology. Owing to privacy concerns, only those phenotypes that were observed 49 times within the cohort were included among the phenotypes chosen for analysis. Utilizing this approach, there were 4841 phenotypes extracted from the EMR. Prevalence of each phenotype can be seen in Supplementary Figure 2 .
One of the challenges in conducting a PheWAS study is balancing sample size and how well the cases and controls are defined. As such, all cases were assigned by either 'rule of one' (individuals only had to have been coded once to be considered a case) or 'rule of two' (defined as occurrence of an ICD9/V code at least twice in the EMR of a given subject). Informed by Monte Carlo power calculations, 'rule of one' was applied for rare conditions (fewer than 300 cases). For more common phenotypes, rule of two was applied where rule of two explained 475% of the cases defined by rule of one. This was a compromise for the added benefit of including more samples at the risk of reducing the positive predictive value. In applying rule of two, any individual coded only once was thus censored from further analysis. No further filtering of phenotypes was conducted, including filtering based on potential environmental effects and/or injury, because of the possibility that those codes could help define symptoms for more complex conditions. For example, a variant associated with broken bones could be indicative of an osteoporotic-like condition.
Rs3135388 was genotyped as part of a larger multiplex Sequenom assay (Sequenome, San Diego, CA, USA) in accordance with the manufacturer's specifications for 384 well format. Primer sequences are available on request. On each 384 plate, a Centre d'Etude du Polymorphisme Humain (CEPH) trio was genotyped along with two negative controls. No Mendelian errors were observed, and the variant was consistent with Hardy-Weinberg equilibrium (P ¼ 0.064).
For common ICD9 and V codes, unadjusted and adjusted logistic regression analysis was conducted. As all patients in this cohort were older 25 PheWAS analysis was conducted in R (http://www.r-project.org). No evidence of strong systematic confounding or bias in the SNPphenotype associations was observed according to the Q-Q plot (Supplementary Figure 3) . Sample size estimates were calculated in R assuming a balanced case-control study utilizing the observed disease prevalence, allele frequency and odds ratios.
